Polycystic Kidney Disease
- 1 Definition/Description
- 2 Prevalence
- 3 Characteristics/Clinical Presentation
- 4 Associated Co-morbidities
- 5 Medications
- 6 Diagnostic Tests/Lab Tests/Lab Values
- 7 Etiology/Causes
- 8 Systemic Involvement
- 9 Medical Management (current best evidence)
- 10 Physical Therapy Management (current best evidence)
- 11 Dietary Management
- 12 Differential Diagnosis
- 13 Case Reports/ Case Studies
- 14 Resources
- 15 Recent Related Research (from Pubmed)
- 16 References
Polycystic Kidney Disease (PKD) is a genetic kidney disease which causes large benign cysts to form on the kidneys. The cysts are fluid filled cavities (seen in Figure 1) that can ultimately impede kidney function leading to degeneration of renal tissue and renal failure.  Cysts can range anywhere from microscopic in size to several centimeters in diameter.  A cyst begins as a protrusion of the nephron and can occur anywhere along its length.  Most cysts detach from the nephron, and eventually enlarge and fill with either clear fluid or fluid that contains blood or white blood cells. 
There are two types of PKD; autosomal dominant and autosomal recessive. Autosomal dominant PKD, or ADPKD, is the most common form of PKD and typically manifests itself in middle aged adults while autosomal recessive PKD is less common and typically manifests itself in childhood. Autosomal recessive PKD is the more serious form and often leads to death in infancy or early childhood.  For a person to inherit ADPKD, it takes a mutated gene from only one parent, while it takes a mutated gene from both parents for a person to inherit ARPKD (see Figures 2 and 3). 
Image available at http://homeopathyworldcommunity.ning.com/forum/topics/adult-polycystic-kidney.
Image found at http://www.pkdcure.org/tabid/1354/Default.aspx.
Image found at http://www.pkdcure.org/tabid/1354/Default.aspx.
ADPKD affects approximately 600,000 Americans; however, the number could actually be higher as many adults who have PKD do not yet exhibit symptoms.  Each child born to a parent with the gene for ADPKD has a 50% chance of inheriting the disease.  Approximately 10% of those in end stage renal failure have ADPKD. 
People with ADPKD may not know they have the disease because their symptoms have not yet manifested themselves. ADPKD signs and symptoms typically begin to show themselves between the ages of 30 and 40.
Symptoms/Signs for PKD include:
• high blood pressure
• back or side pain related to enlarged kidneys
• increase in the size of the abdomen due to enlarged kidneys ( see Figures 4 and 5)
• blood or protein in the urine
• frequent urination
• kidney stones
• kidney failure
• urinary tract or kidney infections
Symptoms that are also associated with PKD include:
• joint pain
• nail abnormalities
• painful menstruation
Figure 5 Image found at
Cardiovascular complications may include high blood pressure or hypertension, cerebral aneurysms, and mitral valve prolapse (MVP). MVP is present in approximately 26% of people who have ADPKD compared to 2%-3% of the general population. Symptoms associated with MVP are heart palpitations, a feeling that the heart is fluttering or racing, and chest pain that is not associated with exercise or exertion. Also, people with ADPKD have approximately a 5%-10% risk of developing intracranial aneurysms. The symptoms of a ruptured aneurysm include sudden severe headache, pain in moving the neck, nausea and vomiting, and loss of consciousness. A person experiencing an intracranial aneurysm will require immediate medical attention as it is a medical emergency. According to the PKD Foundation website, "Patients with ADPKD and a family history of intracranial aneurysms have a higher incidence of developing an aneurysm (22%) and should be screened more frequently."
Many people with ADPKD develop liver cysts; however, they rarely occur in those under the age of 30. Liver cysts tend to develop and grow in size as the person ages. Though this leads to an increase in the size of the liver, the amount of functioning liver tissue remains relatively unvarying. Both genders are susceptible to liver cysts; however women tend to present with cysts at a younger age while men tend to present with more progressive liver disease. Pregnancy is a factor that increases the likelihood and size of liver cysts in women with PKD.
There is no cure for PKD, so the best way to manage it is by controlling or minimizing symptoms. Controlling blood pressure is one of the most important ways to manage PKD. While it is unsure which blood pressure medications are best for the PKD patient population, many nephrologists agree that ACE inhibitors (Angiotensin Converting Enzyme inhibitors) or ARB (Angiotensin Receptor Blockers) are good medications to start with. Both of these medications work via various pathways to block or inhibit angiotensin II; an enzyme that constricts the blood vessels thereby increasing blood pressure.
As stated above, urinary infections are common in people with PKD. Prompt administration of antibiotics for management of kidney, bladder, or urinary tract infections is important for people with PKD as well as drinking plenty of fluids to dilute blood in the urine.
PKD patients should avoid using all NSAID (Non Steroidal Anti Inflammatory Agents) products such as aspirin, Advil, Aleve, etc. unless told to do so by a physician due to the negative effects on the kidneys. Patients with PKD may take acetaminophen (Tylenol) for their back and flank pain. Unlike NSAIDS, acetaminophen does not have the same negative effects on kidney function; however, overtime, usage of acetaminophen can have negative effects on the liver.
Diagnostic Tests/Lab Tests/Lab Values
A urinalysis can be used to determine if there is blood or protein in the urine.  If the disease has progressed the enlarged kidneys may be palpable upon examination.  An ultrasound or CT scan can be used to determine if a malignancy is present, and surgery may be necessary to make a definitive diagnosis.  Genetic testing can also be done by taking and comparing a blood sample from the person and three family members who are either known to have or not have PKD. 
A positive family history of PKD is reported in approximately 75% of cases.  ADPKD results from a genetic mutation on the short arm of chromosome 16.  According to the PKD Foundation website, 85% of mutations in ADPKD occur in chromosome 16 (PKD1 gene) while 15% of mutations in ADPKD occur in chromosome 4 (PKD2 gene): see Figure 6. 
Image found at http://www.pkdcure.org/tabid/1354/Default.aspx.
PKD affects the excretory system, cardiovascular system, and digestive system.
The kidneys act as the major filters of the blood. According to the PKD Foundation website, "the kidneys filter approximately 200 quarts of blood daily, reabsorb 98% of the filtrate and regulate the composition of the blood by removing waste...". Additional kidney functions include the production of three hormones: erythropoietin, renin, and calcitriol. Renin is a very important hormone in the regulation of blood pressure.
PKD affects the cardiovascular system, because, as previously mentioned, it puts the person at risk for hypertension, intracranial aneurysms, and MVP. The fluid filled cysts on the kidneys create a reduction in blood flow which the body attempts to correct by releasing angiotensin II. Angiotensin II causes vasoconstriction thereby increasing blood pressure to in turn increase blood flow. However, the decreased blood flow cannot be corrected due to the pathology of the kidneys, so a "broken feedback loop" ensues. Persistent, long term hypertension can lead to heart damage if left untreated. According to the PKD Foundation website, "approximately 50% of PKD patients die from the heart and vascular complications of PKD, not renal failure."
The liver is the most common site for extra renal cysts to develop; however, cysts can also form on the pancreas. According to the PKD Foundation website, "Current research suggests that liver cysts form from cells lining the bile ducts or tubules of the liver rather than the liver cells themselves." These cysts displace the liver tissue but do not destroy it which is why the liver enlarges but remains relatively functional. Another gastrointestinal complication of ADPKD is diverticulosis. Diverticulosis involves a deformation of the colon and occurs more often in people with PKD who are on dialysis or have had a kidney transplant than any other kidney disease. Also these people tend to have more complications from diverticulosis such as infection known as diverticulitis.
Medical Management (current best evidence)
There is currently no cure for PKD; however, there is a lot of research being done to discover one. Below are some of the drugs and alternate treatments being researched as listed on the PKD Foundation website.
• Plx5568: A Phase II clinical trial is planned by Roche for this drug made by Plexikkon that has been shown to block cell proliferation in pre-clinical testing. Phase I studies evaluating the drug’s safety, dosage and side effects in healthy volunteers has been completed.
• Roscovitine is a drug that blocks cell proliferation and is currently being tested in cancer trials and pre-clinical studies for PKD in cystic mice.
• Pioglitazone is a drug that blocks cell proliferation and is being tested in pre-clinical studies for PKD in cystic mice.
• Reversin is a drug that has been shown to restore kidney function in advanced cystic disease in pre-clinical studies.
• Stem cells from human embryos are being tested as a means to restore kidney function in pre-clinical studies for PKD in cystic mice.
As previously stated, the best way to manage PKD is by controlling or minimizing symptoms. Controlling one's blood pressure, whether through medication, diet, and/or exercise is a good way to slow or prevent the progression of the PKD. According to the PKD Foundation website, "the current goal blood pressure for individuals with ADPKD is less than 130/80". A person can control cardiovascular risk factors by "maintaining a healthy diet, maintaining healthy body weight, exercising regularly, avoiding smoking, etc."
Those people with PKD who reach end stage renal failure will need to undergo dialysis treatments and, ultimately, a kidney transplant. When a person undergoes dialysis, a fluid called dialysate is injected into their bloodstream. This fluid is a mixture of pure water and chemicals that is circulated throughout the blood to help filter out the toxins that the kidneys can no longer fliter. A semi-permeable membrane with microscopic holes separates the dialysate from the blood and allows the toxins to be removed from the blood while not removing necessary substances such as protein and blood cells from the blood stream.
There are two main types of kidney dialysis: hemodialysis and peritoneal dialysis (PD). Hemodialysis involves a person being hooked up to a machine known as a dialyzer which has a man-made semi-permeable membrane which acts as the filter for the kidneys. To begin hemodialysis, a person must discuss with their physician their best options for an access site or port. A person can undergo hemodialysis at a dialysis center, nocturnal hemodialysis, or daily home hemodialysis. A person who chooses to undergo hemodialysis at a dialysis center will come to the center 3 days a week for 3-4 hours a day to be hooked up to the dialyzer machine to have their blood filtered. A person who chooses to do nocturnal hemodialysis will undergo extended treatments 3 or more nights a week while asleep. Finally, if a person chooses to undergo daily home hemodialysis, they will complete 2-3 hour sessions 5-6 days a week. According to the PKD Foundation website, Medicare and private insurance companies may not pay for the extra treatments needed for nocturnal and home hemodialysis. Peritoneal dialysis involves a person filling their abdominal cavity with dialysate via a catheter allowing the peritoneal membrane to act as the semi-permeable membrane. The dialysate stays in the abdominal cavity and pulls the waste through the peritoneal membrane for several hours. The person may manually empty and refill the dialysate 4-5 times per day, or they may choose to have a machine known as a cycler do this automatically while they sleep.
Physical Therapy Management (current best evidence)
Though there is no cure for PKD, there has been research that shows that exercise can help decrease or manage symptoms on people with chronic kidney disease. Many of these studies look at the effect of exercise on the proteinuria, glomerular filtration rate (GFR) and blood pressure. One study found that a 12 week aquatic exercise program improved cardiorespiratory functional parameters, resting blood pressure, proteinuria, and the GFR in patients with chronic kidney disease.
Another study looked at the effects of strength training in elderly patients in the predialysis phase. The authors of the study found that after completion of a 12 week exercise program that included resistance training with 60% of the person’s 1 RM, there was no difference in muscle fiber area or fiber type between the exercise group and the control group which was sedentary. However, there were no disadvantageous effects in the histopathology of the muscle in the exercise group. Thus the authors concluded that 60% of the patient’s 1RM is sufficient to build strength and endurance in the patient population but not to increase muscle fiber area or muscle fiber type.
A third study questioned the number of dialysis patients who might benefit from an exercise program while in the hospital. The authors also looked at the number of patients who adhered to the program as well as the effect of the exercise on the patients’ “10-m shuttle walk test, haemoglobin, body mass index, urea reduction ratio, nutritional status and nine domains of quality of life using the Short Form 36 (SF36) questionnaire”. The results of the study showed that approximately 50% of the hospital haemodialysis patients were interested and able enough to start a dialysis cycling program three times a week. The percentage of the patients that continued the program after 2 months was slightly less than 80% of the starting number. The patients who continued to exercise showed a significant improvement of their walking distance on the shuttle walk test which was correlated with an “improvement in well-being as judged by the quality-of-life scores”. According to the study, “there were no important changes in haemoglobin, nutritional status or effectiveness of dialysis during the 8 weeks of study”.
One way of slowing the progression of PKD is by managing the diet. Many people manage the disease by eating a low sodium and low protein diet and drinking lots of fluids. A person with a chronic kidney disease may have lab work done to determine which nutrients are and are not being processed properly.  With this information, the person may choose to visit a renal dietician to discuss a specific diet customized for the person’s needs.  Fluid intake is also important in the management of PKD and should be discussed with a nephrologist.  People with PKD lose the ability to absorb water efficiently early on in the disease process.  Therefore, a person with PKD may easily become dehydrated during strenuous exercise or extreme heat.  A person who is undergoing dialysis must also monitor fluid intake based on the amount of urine produced and the type of dialysis they are using. If the person is no longer urinating, fluid intake should be limited to 1 liter per day. 
Below is a list of some of the symptoms of PKD. Next to each symptom are listed diseases that can be associated with those symptoms but do not necessarily have a relation to PKD.
Hypertension: heart failure, stroke, MI, arterial aneurysm, diabetes
Blood in the urine: UTI, kidney infection, kidney injury, bladder cancer, STD, hemophilia, leukemia, tuberculosis, endocarditis
Protein in urine: rhabdomyalysis, diabetes, HIV, preeclampsia, eclampsia, UTI, multiple myeloma
Increase in size of abdomen/trunk: irritable bowel syndrome, constipation
Low Back Pain: constipation, ankylosing spondylitis, ascites, endocarditis, ovarian cysts, prostate cancer, sciatica, inflammatory bowel disease
Headache: primary neoplasm, migraine, ischemia, cerebral vascular thrombosis, subarachnoid hemorrhage, hypertension, systemic lupus erythematosus, obstructive sleep apnea, pregnancy, dysmenorrhea, cranial neuralgia, brain abscess, side effects or overuse of medications, caffeine withdrawal, hypoglycemia, fibromyalgia
Case Reports/ Case Studies
- Ultrasonography in Evaluation of Renal Function at Autosomal Dominant Polycystic Kidney Disease: a case report [view article in Internet Journal of Urology]
- Autosomal dominant polycystic kidney disease with diffuse proliferative glomerulonephritis - an unusual association: a case report and review of the literature [[http://ck8zf4yc8t.search.serialssolutions.com.libproxy.bellarmine.edu/?genre=article&isbn=&issn=17521947&title=Journal+Of+Medical+Case+Reports&volume=4&issue=&date=20100429&atitle=Autosomal+dominant+polycystic+kidney+disease+with+diffuse+proliferative+glomerulonephritis+-+an+unusual+association%3a+a+case+report+and+review+of+the+literature.&aulast=D%27Cruz+S&spage=125&sid=EBSCO:MEDLINE&pid= view article in ''Journal of Medical Case Reports'']]
- Pregnancy complicated by Caroli's disease with polycystic kidney disease: A case report and following observations  [view article abstract on Pubmed]
- Technical and Functional Implications of Hand-Assisted Laproscopic Partial Nephrectomy in a Patient with Autosomal Dominant Polycystic Kidney Disease [view article abstract on Pubmed]
- Congenital polycystic kidney disease in one of the twins [view article in Bratislavske Lekarske Listy]
add links to case studies here (case studies should be added on new pages using the case study template)
Recent Related Research (from Pubmed)
- Goodman CC, Fuller KS, Boissonnault WG. Pathology: implications for the physical therapist. 2nd ed. Philadelphia, PA: Saunders; 1998.
- PKD Foundation. The Science of PKD. http://www.pkdcure.org/tabid/1354/Default.aspx (accessed 5 March 2011).
- National Center for Biotechnology Information, U.S. National Library of Medicine. Polycystic kidney disease. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001531 (accessed 5 March 2011).
- National Kidney Foundation. Polycystic Kidney Disease. http://www.kidney.org/atoz/content/polycystic.cfm (accessed 5 March 2011).
- Mayo Clinic. Polycystic kidney disease. http://www.mayoclinic.com/health/polycystic-kidney-disease/DS00245/DSECTION=symptoms (accessed 5 March 2011).
- Mayo Clinic. Acetaminophen (Oral Route, Rectal Route). http://www.mayoclinic.com/health/drug-information/DR601885 (accessed 5 March 2011).
- Pechter U, Ots M, Maaroos J, et al. Beneficial effects of water-based exercise in patients with chronic kidney disease. International Journal of Rehabilitation Research [serial online]. June 2003;26(2):153-156. Available from: CINAHL with Full Text, Ipswich, MA. Accessed March 5, 2011.
- Heiwe S, Clyne N, Tollbäck A, Borg K. Effects of Regular Resistance Training on Muscle Histopathology and Morphometry in Elderly Patients With Chronic Kidney Disease. American Journal of Physical Medicine & Rehabilitation [serial online]. November 2005;84(11):865-874. Available from: Academic Search Premier, Ipswich, MA. Accessed March 5, 2011.
- Torkington M, MacRae M, Isles C. Uptake of and adherence to exercise during hospital haemodialysis. Physiotherapy [serial online]. June 2006;92(2):83-87. Available from: SPORTDiscus with Full Text, Ipswich, MA. Accessed March 5, 2011.
- PKD Foundation. Good Activities for People with Polycystic Kidney Disease (PKD). Available from: http://www.youtube.com/watch?v=kW_vY7DGRuI&NR=1 [last accessed 7 March 2011]
- PKD Foundation. Drinking Water and Polycystic Kidney Disease. Available from: http://www.youtube.com/watch?v=2_RCEwDvRfk [last accessed 7 March 2011]
- Wrong Diagnosis. Causes of Blood in urine. http://www.wrongdiagnosis.com/symptoms/blood_in_urine/causes.htm (accessed 5 March 2011).
- Goodman CC, Snyder TE. Differential Diagnosis for physical therapists: screening for referral. 4th ed. St. Louis, MO: Saunders Elsevier; 2000.
- Yovchevski P, Smilov N, Kostadinova I. Ultrasonography in Evaluation of Renal Function at Autosomal Dominant Polycystic Kidney Disease: a case report. Internet Journal of Urology [serial online]. January 2010;6(2):17. Available from: Academic Search Premier, Ipswich, MA. Accessed March 8, 2011.
- D'Cruz S, Singh R, Sachdev A, et al. Autosomal dominant polycystic kidney disease with diffuse proliferative glomerulonephritis - an unusual association: a case report and review of the literature. Journal Of Medical Case Reports [serial online]. April 29, 2010;4:125. Available from: MEDLINE, Ipswich, MA. Accessed March 8, 2011.
- Tsunoda M, Ohba T, Uchino K, Katabuchi H, Okamura H, Kaneki S. Pregnancy complicated by Caroli's disease with polycystic kidney disease: A case report and following observations. Journal of Obstetrics & Gynaecology Research [serial online]. August 2, 2008;34:599-602. Available from: Academic Search Premier, Ipswich, MA. Accessed March 8, 2011.
- Vaishali K, Christopher Y. N, Yves C, Patrick P.W. L. Case Report Technical and Functional Implications of Hand-Assisted Laparoscopic Partial Nephrectomy in a Patient with Autosomal Dominant Polycystic Kidney Disease. Journal of Endourology [serial online]. June 2007;21(6):625-627. Available from: Academic Search Premier, Ipswich, MA. Accessed March 8, 2011.
- Bartos V, Janciova L, Ivan J, Janos M, Adamicova K, Pec M. Congenital polycystic kidney disease in one of the twins. Bratislavské Lekárske Listy [serial online]. 2010;111(6):353-356. Available from: MEDLINE, Ipswich, MA. Accessed March 8, 2011.